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Abstract
Background: Several small studies found night-time awakenings due to COPD symptoms were associated with
decreased health status. In this study, night-time awakenings in patients with COPD were examined and effects of
tiotropium therapy evaluated.
Methods: This study was a post hoc, exploratory, pooled analysis of twin, multicenter, double-blind, randomized,
placebo-controlled, parallel-group trials. Patients with stable moderate-to-severe COPD were randomized to
tiotropium HandiHaler® (n = 550) or placebo (n = 371) and followed for 13 weeks. During a 2-week, pre-treatment
baseline period and for 13 weeks on treatment, self-reported night-time awakenings due to COPD symptoms,
rescue medication (albuterol) use, and morning and evening peak expiratory flow rate (PEFR) were recorded daily.
Nightly, COPD-related awakenings were scored: 0 = no awakenings; 1 = 1 awakening; 2 = 2–3 awakenings; or 3 =
awake most of the night. Health-related quality-of-life (HRQoL) and energy–fatigue questionnaires were completed
at baseline and during treatment.
Results: Patients were aged 65.2 ± 8.7 years (mean ± SD), with a mean pre-bronchodilator FEV1 of 36.1 ± 13.5 %
predicted normal at baseline. Data for night-time awakenings and albuterol use were available for 543 (99 %)
patients on tiotropium and 352 (95 %) on placebo. At baseline, 280 (51.5 %) patients on tiotropium and 179
(50.1 %) on placebo reported ≥1 COPD-related night-time awakening per week. Over the 13-weeks’ treatment,
tiotropium was associated with fewer night-time awakenings, with mean ± SE overall awakening scores per week of
0.356 ± 0.006 compared with 0.421 ± 0.007 for placebo (p < 0.001); means were significantly lower for tiotropium
versus placebo in patients with baseline awakenings (p < 0.001), but not for those without baseline awakenings.
COPD-related night-time awakenings were associated with increased nocturnal rescue medication use and lower
HRQoL ratings in both treatment arms. Following start of treatment, tiotropium decreased patients’ use of rescue
medication compared with placebo, and morning and evening adjusted means for PEFR were higher for tiotropium
compared with placebo.
Conclusions: Tiotropium is associated with decreased COPD-related night-time awakenings. Night-time awakenings
are associated with increased nocturnal rescue medication use and may be a surrogate marker of symptom control
in patients with COPD.
Keywords: Albuterol, Bronchodilation, COPD, Long-acting anticholinergic, Night-time awakening, Peak expiratory
flow rate, Rescue medication, Tiotropium
* Correspondence: pmacal@liverpool.ac.uk
1Clinical Science Centre, University Hospital Aintree, Longmoor Lane,
Liverpool L9 7AL, UK
Full list of author information is available at the end of the article
© 2016 Calverley et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Calverley et al. Respiratory Research  (2016) 17:27 
DOI 10.1186/s12931-016-0340-9
Background
The onset of sleep poses particular problems for the re-
spiratory system. There is a well-documented circadian
rhythm in lung function, with forced expiratory volume
in 1 s (FEV1) falling by approximately 150 mL overnight
in healthy subjects [1]. This change is enhanced in pa-
tients with asthma, who often complain of nocturnal re-
spiratory symptoms [2], whereas, patients with chronic
obstructive pulmonary disease (COPD) show falls in
overnight FEV1 similar to those seen in healthy individ-
uals [3]. Although sleep quality is known to be poor in
COPD [4, 5], increased nocturnal symptoms in this
population have only been demonstrated recently [6],
and night-time awakening could be considered a poten-
tial surrogate for poor disease control.
The relationship of night-time and morning symptoms
in COPD to changes in lung function is unclear, since
relatively little attention has been paid to recording the
time of day when symptoms are most prevalent. In pa-
tients with COPD, McNicholas et al. [7] found that the
long-acting anti-muscarinic drug tiotropium significantly
reduced the degree of rapid-eye-movement sleep-related
desaturation and improved post-sleep FEV1 compared
with placebo. In comparison with tiotropium alone, the
addition of an inhaled corticosteroid/long-acting beta-
agonist (LABA) combination to tiotropium, was associ-
ated with fewer morning symptoms in patients treated
with this more intensive regime [8]. However, to date,
there are relatively few data available on the impact of
once-daily long-acting inhaled bronchodilators on night-
time symptoms, either as reported by patients, or
reflected in the use of rescue medication to control re-
spiratory symptoms at night or in the morning.
We hypothesized that the use of tiotropium would be
associated with less nocturnal awakening due to respira-
tory symptoms and less rescue medication use at night
and during the first half of the waking day. To test these
hypotheses, we conducted a post hoc analysis of two
identically-designed, randomized, placebo-controlled clin-
ical trials in which night-time awakening and rescue
medication data were available. In addition, the effect of
night-time awakenings on nocturnal rescue medication
use and health status were also evaluated to assess further
the clinical impact of these events.
Methods
Study design
This post hoc exploratory study was a pooled analysis of
twin, multicenter, double-blind, randomized, placebo-
controlled, parallel-group trials, conducted at 50 sites in
the United States. The trials evaluated the efficacy and
safety of tiotropium delivered by a dry powder inhaler in
patients with COPD. Each trial had three phases, a
2-week baseline period, an initial 13-week safety and ef-
ficacy treatment phase, and an extension phase to Week
49 to collect data on long-term lung function and
exacerbations. During the treatment phase, data on
night-time awakenings due to COPD symptoms were
collected over the first 13 weeks only and not during the
extension phase. Efficacy and safety results for the whole
duration of the trials have been reported previously [9].
The primary efficacy endpoint in the original trials was
trough FEV1 change from baseline after 13 weeks of treat-
ment. Pre-specified secondary endpoints included in the
analyses were rescue medication use, morning and evening
PEFR, health-related quality-of-life (HRQoL) measures,
and energy and fatigue scores. These secondary endpoints,
along with scores for night-time awakenings due to COPD
symptoms, were collected from patient diaries and ques-
tionnaires. This is a retrospective study, which reports post
hoc results from twin multicenter studies. In the originat-
ing twin studies, the study protocol was approved by the
Institutional Review Board at each center. The IRB used
most frequently was the Western Institutional Review
Board, 3535 7th Ave. SW, Olympian WA 98502, USA. A
full list of all IRBs could be provided if this is necessary.
All patients gave written informed consent and the
study protocol was approved by the Institutional Review
Board at each center.
Study participants
Study participants were outpatients, aged ≥40 years, with
a >10 pack-years smoking history, and a clinical diag-
nosis of COPD as defined by the American Thoracic
Society [10]. Patients had stable, moderate-to-severe
airway obstruction, with a pre-bronchodilator FEV1
of ≤65 % of predicted normal according to Morris [11]
and a FEV1/forced vital capacity (FVC) of ≤70 %.
Patients were excluded if they had significant disease other
than COPD that might influence the results of the study or
put them at risk if they participated. Other exclusion criteria
included: a history of asthma, allergic rhinitis, or atopy; total
blood eosinophilia ≥600/mm3; and regular use of daytime
oxygen therapy. Patients with a history of heart failure
within 3 years, myocardial infarction within 1 year, or car-
diac arrhythmia treated with drugs were also excluded.
During the study, patients were allowed most con-
comitant medications, with the following restrictions on
respiratory medications. Inhaled anticholinergic drugs
(e.g., ipratropium bromide and atropine) were allowed
during the baseline period but, with the exception of the
study drug, not during the treatment period. Albuterol
rescue medication was allowed as needed throughout
the study. Theophylline preparations (excluding 24-h
preparations), inhaled corticosteroids, and doses of oral
corticosteroids (equivalent to ≤10 mg prednisone daily
or ≤20 mg every other day) were allowed if at a stable
dose for ≥6 weeks prior to screening and throughout the
study period. For acute exacerbations, any additional
medications, including antibiotics, were permitted as
required. However, patients were allowed only two,
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7-day increases in the dose or the addition of oral steroids
or theophylline. Other investigational drugs, all beta
blockers, cromolyn sodium, nedocromil sodium, oral beta-
adrenergics, or LABAs were not allowed for 1 month prior
to the baseline period or throughout the study period.
Patients were excluded if they were taking antihistamines
(H1 receptor antagonists) at screening. Patients not meeting
the concomitant medication requirements were excluded.
Study procedures
Screening and baseline period
At a screening visit, demographic and medical history
data were collected; a 12-lead ECG, physical examin-
ation, pulmonary function testing, laboratory evalua-
tions, and measurement of serum theophylline levels (if
used) were also performed. Spirometry was conducted
to American Thoracic Society standards [12], and % of
predicted normal values were calculated using Morris et
al. [11] and the European Community for Steel and Coal
(ECSC) [13] equations. Qualifying patients entered a 2-
week baseline period, during which time night-time
awakenings, morning and evening PEFR, and albuterol
rescue medication were recorded daily in patient diaries.
The baseline week is defined as Week 0, the week imme-
diately preceding the date of first treatment.
Treatments
After the baseline period, patients were randomized in a
3:2 ratio to tiotropium (18 μg/day tiotropium; Spiriva®;
Boehringer Ingelheim) or matching placebo, taken once
daily at the same time each morning (between 8.00 am
and 10.00 am) from a dry powder inhaler (HandiHaler®;
Boehringer Ingelheim, Ingelheim am Rhein, Germany).
Night-time awakening scores
Night-time awakenings due to COPD symptoms (wheez-
ing, shortness of breath, and coughing) were scored for
each night in the baseline week (Week 0) before treatment
started and for 13 weeks post-randomization. For each
night, patients were asked to score their COPD-related
awakenings using the following scale: 0 for no awakenings;
1 for one awakening; 2 for two or three awakenings; and 3
for being awake for most of the night. Because of the vari-
ability in night-time awakenings over time, a weekly mean
awakening score was calculated for each patient and aver-
aged over 13 weeks. For any given week, if a patient did
not experience any night-time awakenings due to COPD
symptoms his/her weekly mean score was listed as 0 for
that week. For example, for a patient who scored 0 for 3
nights, 1 for 2 nights and 2 for 2 nights, the weekly mean
score was calculated as 6/7 = 0.86.
For subgroup analyses, patients were divided into
those with and those without night-time awakening at
baseline.
Rescue medication use
Rescue medication use, measured by the number of
doses (consisting of one or two puffs) of rescue albuterol
taken over 6-h intervals (6 am to noon, noon to 6 pm,
6 pm to midnight, and midnight to 6 am), was recorded
by patients in their daily diaries. Rescue medication use
was recorded both at baseline and during the 13-week
treatment period. This was used to calculate the number
of doses taken over each 24-h period. For each patient,
weekly means were calculated for each of the four 6-h
periods and for 24 h.
Peak expiratory flow rates
Patients recorded their peak expiratory flow rate (PEFR)
measurements twice daily during the baseline and treat-
ment periods using an AirWatch™ Monitor (Enact
Health Management Systems, Mountain View, CA,
USA). Morning PEFR was measured by patients immedi-
ately upon rising before any medication use. Evening
PEFR was measured before bedtime. Measurements
were recorded in daily diaries and weekly means were
calculated for each patient.
Questionnaires
To assess general HRQoL, the generic, 36-item Short-
Form Health Survey (SF-36®) [14] was administered
prior to randomization and at 13 weeks from start of
treatment. The SF-36 scales were scored separately and
transformed to a scale of 0 to 100, where 0 indicates the
worst and 100 the best HRQoL.
At the end of the baseline period, at the end of Week 1,
and every 3 weeks thereafter until Week 13, patients were
asked three questions related to the perception of their
energy, fatigue, and severity of their respiratory condition
(only baseline and Week 13 data are reported here).
Energy was scored from 1 = very good to 5 = very poor,
fatigue was scored from 1 = very severe to 6 = no fatigue,
and severity of the respiratory condition was scored from
1 = very severe to 6 = no problems at all (see Additional
file 1: Table S1 for full details).
Statistical analyses
Since all statistical analyses were post hoc and explora-
tory, all p-values can only be interpreted as nominal
values. Analyses used the full analysis set, which in-
cluded all treated patients who had baseline data and
data for 2 weeks on treatment. Baseline was defined as
the week before treatment, and baseline values were cal-
culated for each treatment, as opposed to a common
mean across the treatments. For each patient, weekly
means for night-time awakening score, rescue medica-
tion use, and PEFR were calculated from the daily diary
records, and the mean ± standard error (SE) of the
weekly means were calculated and compared across the
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treatment groups. Last observation carried forward was
used for data imputation. For each patient, the “overall
mean” for Weeks 1–13 was calculated as the average of
his/her weekly means.
Analysis of covariance with treatment, baseline, and
pooled centers as covariates was used as the statistical
model. Adjusted means were estimated weekly and over-
all (Weeks 1–13) for night-time awakening, rescue medi-
cation, and morning and evening PEFR. Adjusted means
for SF-36 and energy–fatigue questionnaire scores were
calculated at the pre-specified key time points.
Pearson’s correlation was used to test associations be-
tween variables. To determine the role of night-time
awakening as a marker of disease control, correlations
between night-time awakening and each of the following
variables were calculated using the patients’ weekly
means: rescue medication, SF-36, and energy–fatigue.
For subgroup analyses, patients were split within each
treatment group into two groups: (i) patients who re-
ported at least one night when they had at least one
awakening due to COPD symptoms at baseline (i.e.
night-time awakening score >0) and (ii) patients without
a single night-time awakening due to COPD symptoms
at baseline (i.e. night-time awakening score = 0).
Results
Baseline demographics and clinical characteristics
Of 1287 patients screened, 550 patients were random-
ized to tiotropium and 371 to placebo. The first patient
was enrolled into the trials on the 7 January 1997 and
the last patient completed the 13-week phase on 30
September 1997. Of the patients with baseline data, one
randomized to tiotropium and five to placebo were not
included in the analyses because they had insufficient
data for 2 weeks on treatment.
Patients were predominantly Caucasian, 65 % were
male, with a mean ± SD age of 65.2 ± 8.7 years, smok-
ing history of 61.2 ± 30.6 pack-years, and FEV1 %
predicted of 36.1 ± 13.5 % (ECSC equation [13]).
Baseline demographics and clinical characteristics
were similar between the tiotropium and placebo
treatment groups, and between the subgroups of pa-
tients with and without night-time awakening at
baseline (Table 1).
Data on rescue medication use and night-time awak-
ening were available for 901 patients at baseline, with
51.5 % in the tiotropium and 50.1 % in the placebo
groups reporting at least one night-time awakening per
week.
Table 1 Baseline demographics and clinical characteristics of trial participants
All patients Night-time awakening at baseline No night-time awakening at baseline
Tiotropium Placebo Tiotropium Placebo Tiotropium Placebo
(n = 544) (n = 357) (n = 280) (n = 179) (n = 264) (n = 178)
Age, years 65.11 ± 8.50 65.30 ± 8.84 63.86 ± 8.68 63.56 ± 8.86 66.44 ± 8.12 67.05 ± 8.50
Male, n (%) 363 (66.7) 227 (63.6) 186 (66.4) 115 (64.2) 177 (67.0) 112 (62.9)
Race, n (%)
White 518 (95.2) 330 (92.4) 263 (93.9) 159 (88.8) 255 (96.6) 171 (96.1)
Black 26 (4.8) 25 (7.0) 17 (6.1) 19 (10.6) 9 (3.4) 6 (3.4)
Asian 0 (0.0) 2 (0.6) 0 (0.0) 1 (0.6) 0 (0.0) 1 (0.6)
Body mass index, kg/m2 28.32 ± 5.66 28.07 ± 5.96 28.32 ± 5.58 27.59 ± 6.00 28.32 ± 5.77 28.55 ± 5.89
Alcohol use, n (%)
Non-drinker 284 (52.2) 174 (48.7) 152 (54.3) 89 (49.7) 132 (50.0) 85 (47.8)
Average consumption 259 (47.6) 181 (50.7) 128 (45.7) 89 (49.7) 131 (49.6) 92 (51.7)
Excessive consumption 1 (0.2) 2 (0.6) 0 (0.0) 1 (0.6) 1 (0.4) 1 (0.6)
Smoking history, pack-years 62.59 ± 30.68 59.21 ± 30.53 64.31 ± 32.31 59.25 ± 31.41 60.77 ± 28.80 59.17 ± 29.72
Duration of COPD, years 8.64 ± 7.42 8.05 ± 6.70 8.88 ± 7.56 8.64 ± 7.42 8.38 ± 7.28 7.47 ± 5.84
Rescue medication use/24 h 3.66 ± 2.71 3.44 ± 2.57 4.30 ± 2.92 4.08 ± 2.77 2.99 ± 2.28 2.80 ± 2.18
FEV1, L 1.05 ± 0.41 1.01 ± 0.44 1.05 ± 0.42 1.00 ± 0.42 1.05 ± 0.41 1.02 ± 0.46
FEV1, % predicted (Morris equation [11]) 38.02 ± 14.07 37.44 ± 14.18 36.88 ± 13.75 36.36 ± 13.91 39.22 ± 14.32 38.53 ± 14.41
FEV1, % predicted (ECSC equation [13]) 36.29 ± 13.48 35.74 ± 13.62 35.22 ± 13.20 34.75 ± 13.38 37.43 ± 13.71 36.75 ± 13.82
FVC, L 2.31 ± 0.79 2.23 ± 0.78 2.28 ± 0.79 2.22 ± 0.78 2.35 ± 0.79 2.25 ± 0.78
FEV1/FVC, % 45.96 ± 11.60 45.51 ± 11.70 46.59 ± 11.52 45.52 ± 11.93 45.30 ± 11.67 45.51 ± 11.49
Data are mean ± standard deviation or number of patients (%)
COPD, chronic obstructive pulmonary disease; ECSC, European Community for Steel and Coal; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity
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Night-time awakening scores
Night-time awakening scores per night for all patients
and for the subgroups with and without baseline night-
time awakenings are shown in Fig. 1.
At baseline, adjusted treatment means, calculated from
patients’ weekly means, for night-time awakening score
per night were similar for the tiotropium and placebo
treatment groups (0.466 ± 0.028 and 0.503 ± 0.035, re-
spectively; p > 0.05). At Week 13, adjusted treatment
means were significantly lower for tiotropium compared
with placebo (0.330 ± 0.022 and 0.426 ± 0.027, re-
spectively; p < 0.01). Adjusted overall treatment means
(i.e. averaged over the entire 13-week treatment period)
were also lower for tiotropium compared with placebo
(0.356 ± 0.006 and 0.421 ± 0.007, respectively; p < 0.001).
In the subgroup analysis of patients with baseline night-
time awakening, adjusted treatment means at baseline
were similar for tiotropium and placebo (0.877 ± 0.042
and 0.966 ± 0.052, respectively; p > 0.05), as was the
distribution of night-time awakening scores (Fig. 2).
Adjusted treatment means were significantly lower
for tiotropium compared with placebo at Week 13
(0.568 ± 0.041 and 0.712 ± 0.050, respectively; p <
0.05) and also when averaged over the entire 13-week
treatment period (0.619 ± 0.100 and 0.720 ± 0.013, respect-
ively; p < 0.001).
In the subgroup of patients without baseline night-
time awakenings, the adjusted treatment means were
not significantly different between the tiotropium and
placebo groups at Week 13 (0.088 ± 0.022 and 0.110 ±
0.027, respectively; p > 0.05) or when averaged over the
entire 13-week treatment period (0.087 ± 0.005 and
0.093 ± 0.006, respectively; p > 0.05).
Rescue medication use
At baseline, the mean number of rescue medication
doses per 24-h time period was similar for the tiotro-
pium and placebo treatment groups (mean ± SD, 3.66 ±
2.71 and 3.44 ± 2.57, respectively). Following the start of
treatment, tiotropium decreased patients’ use of rescue
medication compared with placebo (see Additional
file 2: Figure S1).
Fig. 1 Adjusted weekly mean night-time awakening scores per night due to COPD symptoms. Data presented are for all patients and for the
subgroups of patients who did and did not experience at least one night-time awakening due to COPD symptoms at baseline. Night-time awakening
scores were based on the following: 0 for no awakenings; 1 for one awakening; 2 for two to three awakenings; and 3 for being awake for most of the
night. Data are mean ± standard error. The means are adjusted for center effects and baseline. The overall mean is the average over the 13 on-treatment
weekly means. There were no significant differences between tiotropium and placebo for the group of patients with no awakening at baseline at any
time point. *p < 0.05; **p < 0.01; ***p < 0.001 for tiotropium versus placebo
Fig. 2 Baseline distribution of weekly mean scores of night-time
awakening for patients who experienced at least one night-time
awakening. For each night, patients scored: 0 for no awakenings; 1
for one awakening; 2 for two or three awakenings; and 3 for being
awake for most of the night; these scores were used to calculate a
weekly mean for each patient
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The proportions of patients with rescue medication
use at baseline by 6-h time periods were: 84.2 % (759 pa-
tients) from 6 am to noon; 80.5 % (725 patients) from
noon to 6 pm; 80.9 % (729 patients) from 6 pm to mid-
night; and 50.9 % (459/901 patients) from midnight to
6 am;. Weekly mean number of rescue medication doses
per 6-h time periods are shown in Fig. 3a–d. During
each of the 6-h time periods, rescue medication use was
consistently lower for tiotropium compared with placebo
following start of treatment. Throughout the baseline
and treatment periods, rescue medication use was lowest
in the midnight to 6 am period for both the placebo and
tiotropium treatment groups (Fig. 3d).
For both the tiotropium and placebo treatment groups,
weekly mean rescue medication doses taken during the
night-time (6 pm to 6 am) and daytime (6 am to 6 pm)
were strongly correlated both at baseline and throughout
the treatment period (baseline: r = 0.78 for tiotropium
and r = 0.77 for placebo; Weeks 1–13: range r = 0.76–
0.81 for tiotropium and r = 0.70–0.80 for placebo; and
overall [Weeks 1–13]: r = 0.84 for tiotropium and r =
0.78 for placebo; p < 0.001 for all correlations).
Correlation between rescue medication use and night-
time awakenings
Rescue medication use and night-time awakening score
were positively correlated for both the tiotropium and pla-
cebo treatment groups over all time periods (p < 0.001;
Table 2). The strongest correlation was between rescue
medication use from midnight to 6 am and night-time
awakening score (overall [Weeks 1–13]: r = 0.55 for tiotro-
pium and r = 0.61 for placebo; both p < 0.001).
Peak expiratory flow rates
The weekly means for morning PEFR at baseline were
192.3 ± 4.2 L/min for the tiotropium and 192.9 ± 5.8 L/
min for the placebo treatment groups (Fig. 4a) and for
evening PEFR were 206.1 ± 4.5 L/min for tiotropium and
207.4 ± 6.1 L/min for placebo (Fig. 4b). For all treatment
weeks, both morning and evening adjusted means for
PEFR were higher for tiotropium compared with placebo
(all p < 0.05; Fig. 4a and b, respectively).
Questionnaires
After 13 weeks of treatment (Day 92), patients in the tio-
tropium treatment group had greater (i.e., more favor-
able) SF-36 scores for Physical Function, Role Physical,
General Physical Health, and Physical Health Summary
compared with patients receiving placebo (all p < 0.01;
Additional file 3: Figure S2A). In a subgroup analysis at
Week 13, patients without baseline night-time awaken-
ing had higher scores for Physical Function, Physical
Health Summary, and Role Emotional in the tiotropium
group compared with placebo (p < 0.05; Additional file 3:
Figure S2B) and patients with baseline night-time awak-
ening had higher scores for General Physical Health and
Fig. 3 Adjusted weekly mean rescue medication doses/6-h periods; a 6 am to noon, b noon to 6 pm, c 6 pm to midnight, and d midnight to
6 am. A dose of rescue medication use was defined as one or two puffs of albuterol. Data are mean ± standard error. The means are adjusted for
center effects and baseline. The overall mean is the average over the 13 weekly means. *p < 0.05; **p < 0.01; ***p < 0.001 for tiotropium versus placebo
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Physical Health Summary in the tiotropium group com-
pared with placebo (p < 0.01 and p < 0.05, respectively;
Additional file 3: Figure S2C). Patients without baseline
night-time awakening had a larger treatment effect for
Role Physical, Bodily Pain, Role Emotional, and General
Mental Health compared with those with baseline night-
time awakening, conversely, patients with baseline night-
time awakening had a larger treatment effect for Vitality.
In both the tiotropium and placebo treatment groups,
there were negative and broadly consistent correlations
at baseline and Week 13 between night-time awakening
scores and each of the SF-36 domains (all p < 0.001; see
Additional file 4: Table S2). For tiotropium, correlation
coefficients were in the ranges: r = −0.297 to −0.216 at
baseline and r = −0.233 to −0.175 at Week 13, and for
placebo: r = −0.326 to −0.213 at baseline and r = −0.380
to −0.208 at Week 13. Correlations between the overall
mean for Weeks 1–13 for night-time awakening scores
and SF-36 domain scores at Week 13 were also investi-
gated and gave broadly similar results to those seen for
the Week 13 comparisons (all p < 0.001; see Additional
file 4: Table S2).
Results for the energy, fatigue, and severity of condi-
tion questionnaire are presented in the Additional file 5:
Tables S3 and S4.
Discussion
This analysis has shown that night-time awakenings due
to COPD symptoms were present at baseline in around
half of the patients studied. Tiotropium treatment was
associated with decreased night-time awakenings. These
awakenings were correlated with the use of rescue medi-
cation and, to a lesser degree, impairment of health sta-
tus and increased fatigue, suggesting that night-time
awakening could be a potential surrogate for poor dis-
ease control.
Although considerable effort has been made to pro-
duce validated questionnaires that capture the time
course of exacerbations, well-being, and fatigue in pa-
tients with COPD [15–17], similar attention has not
been paid to the occurrence of symptoms at night or
early in the morning. This study used data from a sim-
ple, non-linear, scoring system that provided a semi-
quantitative assessment of whether COPD symptoms
were present at night. There was evidence of night-to-
night variation in symptomatology, with some nights
being worse than others. Hence, to capture events
throughout the study, data were averaged over 7-day pe-
riods and patients who did and did not experience awak-
enings on at least one night due to respiratory
symptoms were identified. During the baseline run-in
phase (Week 0), half of the patients experienced at least
Table 2 Pearson’s correlation coefficients: weekly mean rescue




n r n r
24 h
Baseline 544 0.30*** 357 0.34***
Overall (Weeks 1–13) 543 0.41*** 352 0.39***
6 pm to 6 am
Baseline 544 0.39*** 357 0.40***
Overall (Weeks 1–13) 543 0.48*** 352 0.51***
6 pm to midnight (12 am)
Baseline 544 0.24*** 357 0.26***
Overall (Weeks 1–13) 543 0.34*** 352 0.31***
Midnight (12 am) to 6 am
Baseline 544 0.47*** 357 0.43***
Overall (Weeks 1–13) 543 0.55*** 352 0.61***
6 am to 6 pm
Baseline 544 0.20*** 357 0.25***
Overall (Weeks 1–13) 543 0.32*** 352 0.26***
***p < 0.001
Fig. 4 Adjusted weekly mean a morning and b evening peak
expiratory flow rates. Data are mean ± standard error. The means are
adjusted for center effects and baseline. The overall mean is the
average over the 13 weekly means for tiotropium versus placebo.
*p < 0.05; **p < 0.01; ***p < 0.001 for tiotropium versus placebo
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one night with respiratory symptoms that caused night-
time awakening. Night-time awakening score was corre-
lated with the use of rescue medication during the base-
line period and overall (Weeks 1–13), with correlation
coefficients in the range 0.3–0.5. This moderate correl-
ation reflects, in part, the use of rescue therapy for other
reasons and the fact that, although symptoms may
awaken a patient, they are not always severe enough for
them to seek inhaled treatment. Nonetheless, the correl-
ation between rescue therapy and this important clinical
symptom of COPD, suggests that this relatively easily
monitored variable may be useful in evaluating how well
the disease is controlled, as is commonly used for assess-
ment of asthma control [18]. In the placebo group, the
night-time awakening scores were similar at baseline
through to Week 13 indicating a consistency in the data,
and suggesting that patients who report symptoms at
night are likely to find this a persistent problem.
Tiotropium is an effective long-acting inhaled bron-
chodilator with duration of action of more than 24 h;
this effect is supported in this study by the observed im-
provement in morning PEFR. Tiotropium’s long duration
of action is also supported by its effect on night-time
awakening. Although during the baseline period, the
likelihood of patients reporting night-time awakenings
was similar in both groups, by Week 13 there was a sig-
nificant reduction in these events in patients treated
with tiotropium as compared with placebo (adjusted
overall treatment means 0.356 and 0.421, respectively;
p < 0.001). This difference achieved statistical significance,
but its clinical importance is questionable. However, the
data are the mean of scores from many patients whose
night-time awakenings were relatively infrequent (see
below). The treatment effect was evident in those who
had reported night-time awakenings during the run-in
period and were experiencing the symptoms of interest
when randomized to treatment. The improvement in
night-time symptoms in the tiotropium-treated group was
paralleled by reduced rescue medication use, which was
seen throughout the 24-h day. Although rescue medica-
tion use was lowest between midnight and 6 am, there
were still significantly fewer doses taken by patients re-
ceiving tiotropium compared with those receiving placebo
over this time period (significantly fewer for seven out of
13 weeks and for the overall Weeks 1–13 mean). There
were also positive effects on health status and overall
levels of fatigue from the intervention, but how much of
this could be attributed to the decrease in night-time
symptoms is hard to assess. Improvements in early morn-
ing symptoms have been reported with other bronchodila-
tor combinations and with other long-acting inhaled
bronchodilators [19], although these changes have not
always been confirmed when assessed in larger patient
groups [20]. Nevertheless, it seems likely that an
improvement in lung mechanics overnight will either
suppress the production of symptoms or possibly in-
crease the threshold of lung function impairment that
needs to be achieved to trigger an awakening. At
present there are insufficient data to know which
mechanisms are more important. Other studies look-
ing at the effect of tiotropium on awakenings have
failed to show an effect, likely due to limitations in
study design [21]. This emphasizes the difficulty of ap-
plying existing questionnaire methodology where random
differences in initial night-time awakenings can occur be-
tween treatment groups, as was the case with the Beier
et al. study [21].
In this study of patients with moderate-to-severe
COPD, only half the patients reported night-time awak-
enings at baseline due to COPD symptoms. This is in
line with other studies, where the percentage of baseline
night-time awakenings varied between 35 % and 57 % of
patients [22, 23]. However, this may underestimate the
true impact of night-time symptoms, as a cross-sectional
European survey of 2807 patients found that 78 % of pa-
tients with COPD reported night-time sleep distur-
bances; a problem that worsened with disease severity
[24]. Clearly, effective control of COPD-related symp-
toms is needed across the 24-h day.
This post hoc analysis has a number of limitations. In
this study, the majority of patients had only a limited
number of night-time awakenings at baseline, which
may have reduced the ability to show strong treatment
effects. In addition, the clinical impact of the findings is
unknown, as the minimal clinically important difference
for night-time awakening is not established and warrants
further investigation. The studies reported here were
undertaken in 1997, at a time when background medica-
tions, such as inhaled LABAs and corticosteroids, were
less commonly used than is now the case. While this al-
lows us to explore the impact of sustained bronchodila-
tion on night-time symptoms and rescue bronchodilator
use, it may be less representative of current therapy,
which may include other long-acting bronchodilators
alone or in combination. In this study, LABAs were not
permitted for at least 1 month prior to the beginning of
the baseline period or throughout the study period and
inhaled corticosteroids were permitted if at a stable dose
for at least 6 weeks prior to screening and throughout
the study period. Furthermore, as noted, the metrics for
night-time awakenings were relatively crude and did not
take account of individual night-time variability; this is
an area that merits further exploration. Likewise, the de-
velopment of more specific, validated questionnaires bet-
ter able to quantify the impact of night-time symptoms
would be useful. Finally, it would help to have data from
a healthy, age-matched control population to understand
the influence of age-related impairment on sleep quality
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that is not COPD related. However, in this study, patients
were asked to only consider awakenings that they felt were
triggered by their respiratory symptoms. Despite these
limitations, we believe that our data represent the impact
of sustained bronchodilation in patients with COPD not
selected on the basis of prior nocturnal symptoms and
hence are applicable to ‘real-world’ patients.
Conclusions
In conclusion, it was found that significant nocturnal
awakenings correlated with COPD symptoms, and were
present at least once weekly in half of the study patients
during the baseline period. These events likely contribute
to overall health status impairment. While it cannot be
stated with certainty that amelioration of these night-time
events positively affects health status, experience in asthma
suggests that this may be the case. Encouragingly,
morning-dosed tiotropium appears to decrease night-time
symptoms and reduce the need for rescue treatment.
However, these data also indicate that the problem is not
abolished, and so further studies are required to explore
the etiology of night-time awakening in this patient popu-
lation, and whether different or more intensive treatments
can favorably impact this potentially troublesome problem.
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